The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top Upgrades: 

• JPMorgan upgraded Pinterest (PINS) to Overweight from Neutral with a price target of $40, up from $35. The firm believes the company has made solid progress across its 2023 investor day priorities to grow users and deepen engagement, improve monetization, and drive profitable growth.

• Evercore ISI upgraded Block (XYZ) to Outperform from In Line with a price target of $75, up from $58, implying 21% upside. The firm says Cash App lending will not be as aggressive as it thought coming out of the company's Q1 earnings.

• Wells Fargo upgraded Cardinal Health (CAH) to Overweight from Equal Weight with a price target of $179, up from $136. The firm sees the improved valuation as justified by strong industry backdrop, improving mix, and execution.

• Redburn Atlantic upgraded Advance Auto Parts (AAP) to Neutral from Sell with a price target of $45, up from $28. Although Advance is yet to make meaningful progress with its turnaround and concerns regarding its investment plan and balance sheet remain, the company will benefit from the favorable second half of 2025 backdrop, the firm tells investors in a research note.

• B. Riley upgraded Kymera Therapeutics (KYMR) to Buy from Neutral with a price target of $60, up from $38. The company released the first-in-human data for KT-621, its oral STAT6 degrader, and it is "fair to say the program passed a key test," not just in terms of target engagement, but, importantly, safety, the firm tells investors in a research note.

Top Downgrades:

• JPMorgan downgraded Bumble (BMBL) to Underweight from Neutral with an unchanged price target of $5. The shares have traded up 50% since President Trump's "Liberation Day" and are now 10% above the price target, the firm notes, adding that it struggles to justify raising the price target given its expectation for Bumble's revenue and payer declines to accelerate, regardless of the macro environment.

• Citizens JMP downgraded Blueprint Medicines (BPMC) to Market Perform from Outperform without a price target given the proposed acquisition by Sanofi (SNY). Shareholders should vote in favor of this acquisition as the offer is fair and competing bids are unlikely, the firm tells investors in a research note. Stephens also downgraded Blueprint Medicines to Equal Weight from Overweight with a price target of $135, down from $150.

• Cantor Fitzgerald downgraded Sprout Social (SPT) to Neutral from Overweight with a price target of $24, down from $38, following a transfer in analyst coverage. The company is already building broad capabilities to enable greater integration with networks and commerce capabilities, but to date, the Social Networks are "still in a holding pattern, trying to figure out their own strategies for how much to open platforms up to third-party platforms," the firm tells investors.

• BMO Capital downgraded MAC Copper (MTAL) to Market Perform from Outperform with a price target of $12.25, up from $11, after the company entered into a binding agreement with Harmony Gold Mining Company (HMY) and Harmony Gold Australia under which it is proposed that Harmony Australia will acquire 100% of the issued share capital in MAC.